Earnings ·
Autolus Therapeutics plc reported second quarter 2026 financial results, announcing net product revenue of $45.7…
AUTLAutolus Therapeutics plc
Autolus Therapeutics plc reported second quarter 2026 financial results, announcing net product revenue of $45.7 million for the three months ended June 30, 2026, a 119% increase year-over-year. The company raised its full-year 2026 net product revenue guidance to $140–$150 million from $120–$135 million and reported a gross margin of 55%, up from negative margins in prior periods. Autolus secured a five-year, interest-only credit facility with Perceptive Advisors for up to $250 million, with an initial $75 million funded at closing on July 30, 2026. The company also completed a workforce reduction affecting approximately 13% of employees to reduce operating expenses by roughly $15 million annually starting in 2027. Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing and delivering next-generation T cell therapies for cancer and autoimmune diseases.